Left atrial appendage closure: prevalence and risk of device-associated thrombus formation
- PMID: 30881888
- PMCID: PMC6382664
- DOI: 10.21037/cdt.2018.10.05
Left atrial appendage closure: prevalence and risk of device-associated thrombus formation
Conflict of interest statement
Conflicts of Interest: Horst Sievert has either ownership interests, stock options, received travel reimbursement, study honoraria or consultant fees for 4tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Cibiem, CGuard, Comed B.V., Contego, CVRx, Edwards, Endologix, Hemoteq, InspireMD, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, pfm Medical, Recor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, Vivasure Medical, Venus, Veryan. The other author has no conflicts of interest to declare.
Comment on
-
Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation.J Am Coll Cardiol. 2018 Apr 10;71(14):1528-1536. doi: 10.1016/j.jacc.2018.01.076. J Am Coll Cardiol. 2018. PMID: 29622159
References
-
- Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24. 10.1161/CIRCULATIONAHA.110.976449 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources